{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-022759","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.004814+00:00","generated_at":"2026-05-22T13:46:25.177496+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Bioworks Q1 revenue up 27% to $48M, guided revenue raised; net loss narrows to $91M","bullets":["Q1 2025 total revenue $48M (+27% YoY); core revenue ex-deferred release $41M (+8%). GAAP net loss $(91)M vs $(166)M prior year.","Adjusted EBITDA $(47)M improved from $(117)M; cash & equivalents $517M.","Raises FY2025 total revenue guidance to $167-187M (from $160-180M); Cell Eng. guidance $117-137M.","Cost reduction target: $250M annualized by Q3 2025; achieved $205M run-rate in Q1.","Awarded $29M ARPA-H contract for distributed manufacturing using wheat germ cell-free systems."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-022759","json":"https://secwatch.observer/filing/0001628280-25-022759.json","markdown":"https://secwatch.observer/filing/0001628280-25-022759.md","text":"https://secwatch.observer/filing/0001628280-25-022759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/0001628280-25-022759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/dna-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:46:25.177496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}